🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ADMA Biologics, Inc. ADMA R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.admabiologics.com
Company Profile ↓
$9.62
-44.07% 1Y
Mkt Cap$2.15B
P/E13.74
P/B5.89
52W High$20.38
52W Low$7.60
Book Value$1.68
EPS (TTM)$0.70

Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 41.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 34.5%.

Steady Revenue Expansion

Revenue has grown at a 59.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 13.7, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 33.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $510.17M (+19.6% YoY); net profit $146.93M.
  • Trailing 12 Months Year-on-year growth — revenue +15.9%, earnings -25.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 59.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:59.18%
1 Year:15.90%

Compounded Profit Growth

5 Years:-
1 Year:-25.67%

Stock Price Performance

1 Year:-44.07%
6 Months:-37.49%
3 Months:+20.70%
1 Month:-4.37%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 16% of range
$7.60 $20.38
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)54.87 · Neutral
Price Performance
1M-4.37%
3M+20.70%
6M-37.49%
1Y-44.07%
Valuation vs Sector

P/E of 13.74 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 41.9%.
  • Healthy ROCE of 34.5%.
  • Excellent profit margin of 33.0%.
  • Compounding revenue at 59.2% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 52.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.74
Industry PE
25.17
Forward P/E
9.87
PEG Ratio
-
Book Value
$1.68
Price to Book
5.89
P/S
4.33
EV/EBITDA
196.16
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
59.18%
Profit 5Y
-
Revenue (YoY)
15.90%
Earnings (YoY)
-25.67%

Profitability & Returns

ROCE
34.51%
ROE
41.90%
ROA
21.78%
Profit Margin
32.98%
Op Margin
-
Gross Margin
64.70%
EPS (Latest Qtr)
$0.16
EPS (TTM)
$0.70

Balance Sheet & Liquidity

Debt/Equity
1.11
Quick Ratio
3.62
Current Ratio
6.97
Debt
$97.67B
Total Assets
$684.21M
Current Assets
$511.17M
Working Capital
$396.97M

Ownership

Promoter Holding
1.97%
Chg in Prom Hold
0.07%
FII / Inst Holding
93.26%
Chg in FII Hold
-0.03%

Financial Snapshot

Enterprise Value
$2.15B
Total Revenue (TTM)
$512.28M
EBITDA
$224.19M
Free Cash Flow
$54.76M
Operating Cash Flow
$136.72M
Shares Outstanding
223.98M
Gross Margin
64.70%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADMA ADMA Biologics, Inc. R2KR3KPHARMA 9.62 13.74 $2.15B 0.00% 34.51% 41.90% 59.18% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --------------------7.79M10.28M16.05M17.83M20.68M29.10M33.91M41.09M56.91M60.12M67.28M81.88M107.19M119.84M114.80M121.98M134.22M139.16M114.49M124.39M
Cost of Revenue ----------------------------------53.70M54.76M58.60M50.35M33.74M-
Gross Profit 583.53K559.50K498.25K593.48K523.62K739.63K857.47K927.50K1.20M1.01M-934.62K-6.56M-----------1.72M-1.00M385.34K3.66M7.77M9.66M16.51M16.69M24.65M39.11M57.45M59.66M61.10M67.23M75.63M88.82M80.75M86.28M
Operating Expenses ----------------------------------26.22M24.43M24.61M26.07M30.46M-
Operating Income -5.68M-3.59M-3.04M-3.20M-3.52M-4.66M-4.16M-5.49M-3.74M-5.94M-8.40M-14.43M-16.53M-13.42M-13.79M-16.55M-13.21M-11.34M-9.05M-16.77M-17.12M-13.80M-15.16M-15.58M-14.44M-14.82M-9.17M-9.32M-813.00K-473.00K8.69M21.82M39.20M39.64M34.88M42.80M51.01M62.75M50.29M52.45M
EBITDA ----------------------------------37.39M43.99M51.21M65.27M61.07M-
Interest Expense ----------------------------------1.98M1.83M1.68M1.63M2.10M-
Pretax Income ----------------------------------33.45M40.10M47.52M61.59M57.13M-
Tax Provision ----------------------------------6.55M5.88M11.09M12.22M11.80M-
Net Income -5.90M-3.96M-3.38M-3.61M-4.68M-5.10M-4.61M-6.01M-4.33M-6.54M-9.04M-15.20M-17.82M-14.75M-15.14M-18.04M-13.07M-13.21M-11.44M-19.25M-20.18M-16.92M-18.38M-18.91M-17.71M-25.01M-13.76M-14.90M-6.79M-6.37M2.56M17.81M32.06M35.91M26.90M34.22M36.43M49.38M45.33M37.82M
Diluted EPS ---------------------0.23-0.19-0.16-0.15-0.13-0.13-0.07-0.08-0.03-0.030.010.080.130.150.110.140.150.200.190.16
R&D Expense 4.33M1.78M1.48M1.40M1.51M2.11M2.03M3.40M1.68M1.19M1.36M1.81M965.57K1.04M1.00M917.30K870.63K516.99K491.40K1.53M1.66M1.71M987.65K1.16M770.56K624.11K873.39K1.04M855.00K1.40M596.00K450.00K560.00K412.00K826.00K1.03M1.53M-2.60M6.01M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 761.04K1.12M3.07M5.92M7.18M10.66M22.76M16.99M29.35M42.22M80.94M154.08M258.21M426.45M510.17M
Cost of Revenue -----------118.81M169.27M206.90M217.41M
Gross Profit 553.47K449.06K1.04M2.17M2.87M4.30M-6.40M-25.21M--19.07M1.17M35.27M88.94M219.55M292.76M
Operating Expenses -----------74.63M67.31M80.57M101.32M
Operating Income -4.62M-7.91M-15.04M-16.02M-15.51M-17.33M-39.31M-60.29M-41.42M-64.91M-58.37M-39.37M21.63M138.98M191.44M
EBITDA ------------39.51M5.12M147.69M197.86M
Interest Expense -----------19.28M25.03M13.93M7.11M
Pretax Income ------------65.90M-28.24M125.71M182.66M
Tax Provision -----------00-71.96M35.73M
Net Income -5.90M-7.30M-15.53M-16.81M-17.97M-19.52M-43.76M-65.74M-48.28M-75.75M-71.65M-65.90M-28.24M197.67M146.93M
Diluted EPS ----------0.88-0.51-0.33-0.130.810.60
R&D Expense 646.76K3.47M9.30M9.52M7.02M7.69M5.57M3.93M2.34M5.91M3.65M3.61M3.30M1.81M4.76M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -2.93M15.56M31.98M27.02M23.71M23.69M108.02M88.88M127.09M207.67M-348.46M329.18M488.68M624.24M
Current Assets ------------270.40M257.01M331.41M466.51M
Cash & Equivalents 228.97K87.77K12.54M26.15M17.20M10.44M9.91M43.11M26.75M26.75M55.92M-86.52M51.35M103.15M87.63M
Inventory ------------163.28M172.91M170.24M206.47M
Receivables ------------15.51M27.42M50.00M158.43M
Total Liabilities -2.54M6.13M10.41M21.01M22.89M28.14M67.69M69.11M100.90M119.42M-196.49M193.98M139.66M146.92M
Current Liabilities -2.30M1.82M3.66M4.20M4.22M11.22M9.44M9.63M14.03M19.95M-39.27M49.81M55.54M69.54M
Long Term Debt ------1.79M2.76M2.76M0--142.83M130.59M72.34M69.33M
Total Debt ------------154.44M141.42M82.12M79.89M
Total Equity -3.93M385.82K9.42M21.57M6.01M820.97K-4.46M40.33M19.77M26.19M88.25M-151.97M135.21M349.02M477.32M
Shares Outstanding ------------221.82M226.06M236.62M239.79M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.43M-6.90M-10.89M-14.70M-15.42M-18.27M-37.27M-62.68M-76.19M-102.00M--59.51M8.80M118.67M50.40M
Investing Cash Flow -270-118.85K-3.13M-4.04M-1.74M904.58K15.21M-2.10M-3.81M-12.72M--13.91M-4.98M-8.57M-21.89M
Financing Cash Flow 1.29M19.47M27.63M9.80M10.40M16.84M60.75M42.92M80.00M143.90M-108.85M-38.99M-58.30M-44.02M
Capital Expenditure -270-118.85K-196.63K-2.32M-26.07K-73.41K-2.68M-2.10M-3.81M-12.73M--13.91M-4.98M-8.57M-22.89M
Free Cash Flow -1.43M-7.02M-11.08M-17.03M-15.44M-18.34M-39.95M-64.77M-80.01M-114.73M--73.42M3.82M110.10M27.50M
Net Change in Cash -----------35.43M-35.17M51.80M-15.52M
Share Buybacks 0150.00K----------0031.94M

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 72.7%40.2%34.0%36.7%39.9%40.3%-28.1%-148.4%--45.2%1.4%22.9%34.4%51.5%57.4%
Operating Margin % -607.5%-707.4%-490.4%-270.8%-216.1%-162.6%-172.7%-354.9%-141.1%-153.8%-72.1%-25.5%8.4%32.6%37.5%
Net Margin % -775.7%-653.0%-506.2%-284.2%-250.4%-183.1%-192.3%-387.1%-164.5%-179.4%-88.5%-42.8%-10.9%46.4%28.8%
ROE % -1,530.1%-77.5%-72.0%-279.8%-2,188.9%437.8%-108.5%-332.5%-184.3%-85.8%--43.4%-20.9%56.6%30.8%
ROCE % -740.6%-57.6%-53.1%-70.2%-79.6%-139.1%-39.9%-76.1%-36.6%-34.6%--12.7%7.7%32.1%34.5%

Shareholding Pattern

Insiders
1.97%
Institutions
93.26%
Public Float
95.14%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 17.12% 38.36M $358.24M
2 State Street Corporation 7.64% 17.12M $159.86M
3 Vanguard Capital Management LLC 4.51% 10.10M $94.37M
4 Vanguard Portfolio Management LLC 4.50% 10.09M $94.23M
5 Rubric Capital Management LP 4.17% 9.34M $87.23M
6 Capital Research Global Investors 3.91% 8.76M $81.78M
7 First Trust Advisors LP 3.48% 7.80M $72.84M
8 Geode Capital Management, LLC 2.71% 6.06M $56.60M
9 Caligan Partners, LP 2.56% 5.73M $53.47M
10 Shaw D.E. & Co., Inc. 2.35% 5.27M $49.26M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADMA

Yahoo Finance Fri, 04 Sep 2026

Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance hu, 06 Aug 2026

ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...

ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.

Yahoo Finance Wed, 05 Aug 2026

ADMA Biologics Q2 Earnings Call Highlights

ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year finan…

Yahoo Finance Fri, 31 Jul 2026

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.

Yahoo Finance Wed, 29 Jul 2026

Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, i…

Yahoo Finance Mon, 27 Jul 2026

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day.

ADMA — Frequently Asked Questions

What is the current share price of ADMA Biologics, Inc. (ADMA)?

As of 2026-09-07 16:24 PDT, ADMA Biologics, Inc. (ADMA) trades at $9.62 on NasdaqGM. Its 52-week range is $7.60 to $20.38.

What is the market capitalisation of ADMA?

ADMA Biologics, Inc. (ADMA) has a market capitalisation of $2.15B on NasdaqGM.

What is the P/E ratio of ADMA?

ADMA trades at a trailing price-to-earnings (P/E) ratio of 13.74. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.89.

What is the return on equity (ROE) of ADMA?

ADMA has a return on equity (ROE) of 41.90%. Its return on capital employed (ROCE) is 34.51%.

Is ADMA a good stock to buy?

This page provides a data-driven analysis of ADMA Biologics, Inc. (ADMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space